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Abstract
Background: Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis in children worldwide. Among
anti-inflammatory cytokines, interleukin-10 (IL-10) is a key immunosuppressive cytokine involved in the pathogenesis of
JIA. To date, only a few studies concerned the association of interleukin-10 gene polymorphisms with JIA. In this study,
we aimed to investigate 3 cytokine single-nucleotide polymorphisms situated at positions -1082(G/A), −819(C/T),
and −592(C/A) in the promoter region of the IL-10 gene to determine whether this polymorphism could be a
marker of susceptibility to JIA in Egyptian children and adolescents. We also measured the serum level of IL-10 to
assess its relation to such polymorphism.
Methods: This was a case-control study included 100 patients diagnosed with JIA, and matched with age, gender,
ethnicity 100 healthy control subjects.
Interleukin-10 −1082(G/A), −819(C/T), and −592(C/A) polymorphisms were genotyped by amplification refractory
mutation system- polymerase chain reaction (ARMS)-PCR methodology, while the serum IL10 levels were measured by
ELISA method.
Results: Compared to the controls subjects, the frequency of IL-10- AA genotype and A allele at the –1082 position
were overrepresented in patients with JIA (OR = 2.7; 95% CI: 1.1–6.4 for the AA genotype; P <0.05 and OR: 1.5;
95% CI: 1.03–2.3 for the A allele; P <0.05 respectively). On the other hand, no significant differences were found
between the 2 groups in the genotype or allele frequencies for the –819 and –592 positions. Of note, we found
a significant positive association between the IL-10 (-1082) AA genotype and susceptibility to polyarticular JIA
(OR: 4.3; 95% CI: 1.5–12.7; P <0.01). We observed that patients with the IL-10 (-1082) AA genotype had significantly
lower serum IL-10 levels (2.3 ± 0.9 pg/ml) compared to those with AG genotype (7.6 ± 1.5 pg/ml) and GG genotype
(9.5 ± 1.2 pg/ml); P < 0.01, respectively.
Conclusion: We demonstrate for the first time, to the best of our knowledge, that the presence of an A allele or AA
gene variant at the –1082 position of the promoter region of the interleukin-10 gene may constitute risk factors for
developing JIA in Egyptian children and adolescents. Moreover, we observed a significant positive association between
the IL10 –1082 AA gene variant and susceptibility to polyarticular JIA.
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Background
Juvenile idiopathic arthritis (JIA) is defined as arthritis in
a child under the age of 16 years affecting one or more
joints, lasting for at least 6 weeks and currently having
no other known etiology [1]. JIA is the most common
autoimmune inflammatory joint disease, with an inci-
dence of 2.6 to 23 cases per 100,000 children per year
[2]. JIA may lead to long-term morbidities such as uve-
itis, depression, osteoporosis, poor pain control, and
even severe disabilities due to joint damage [3]. The
mechanism underlying joint damage in JIA is complex
and involves a variety of molecular and cellular pro-
cesses that may be influenced by genetic factors [4].
Cytokines have been implicated in the development
and perpetuation of inflammatory response in JIA [5].
During active disease, cytokine concentrations in plasma
of patients with JIA increased 2 to 35‐fold [6]. A central
feature of JIA is a relative imbalance of cytokine profile,
with a relative excess of pro-inflammatory molecules in-
cluding interleukin-1, interleukin -6, and tumor necrosis
factor (TNF-α) compared with anti-inflammatory media-
tors such as interleukin -10 [7]. This idea has raised a
great deal of interest in the role of the immunologic sys-
tem in the pathogenesis of JIA.
Interleukin-10 (IL-10) is a key immunosuppressive
cytokine that is produced by a wide range of leukocytes,
as well as non-hematopoietic cells [8]. An earlier study
by Hart et al. reported that IL-10 can effectively block the
production of the pro-inflammatory cytokines IL-1, IL-8,
and TNF-α by snivel macrophages and synoviocytes. IL-
10 was also correlated with an increased autoantibody
production and B cell activation in RA patients [9].
Previous studies revealed increased levels in plasma
and synovial fluid of some inflammatory cytokines in pa-
tients with JIA [10, 11]. Prahalad et al. [10] compared
serum cytokine levels between 77 children with different
JIA subtypes and 81 age-matched healthy controls. The
authors reported that IL10 was significantly elevated in
patients with polyarticular as well as systemic JIA. This
research added that IL-6 and TNF-α were positively
associated with JIA, while IL10 might have a protective
effect on disease, as might be anticipated by its inhibi-
tory activity.
Despite these studies, the association of interleukin-
10 levels with JIA does not constitute proof of cause.
One way to clarify the issue of causation involves a
genetic approach. The IL-10 gene has been mapped
to chromosome 1q31-32, and three single nucleotide
polymorphisms (SNPs) in the promoter region at po-
sitions -1082(G/A), −819(C/T), and −592(C/A) have
been described [12]. Polymorphisms within genes en-
coding inflammatory cytokines are known to alter the
production of cytokines [13]. To date, only a few
studies concerned the association of interleukin-10
gene polymorphisms with JIA and the susceptibility
to JIA.
On the basis of these considerations, we designed this
study to investigate 3 cytokine single-nucleotide poly-
morphisms situated at positions −1082(G/A), −819(C/T),
and −592(C/A) in the promoter region of the interleukin-
10 gene to determine whether this polymorphism could
be a marker of susceptibility to JIA in Egyptian children
and adolescents. We also measured the serum level of IL-
10 to assess its relation to such polymorphism.
Methods
This was a prospective case-control study performed in
Zagazig University Hospitals, and outpatient clinics in
the same hospitals from April 2014 to October 2016.
This study was approved by the ethical committee of
Zagazig University, Egypt and written informed consent
from parents (and where appropriate patients) was pro-
vided in accordance with the Declaration of Helsinki.
One hundred children and adolescents; who had JIA
as diagnosed in the Department of Pediatrics in the
same hospital, were enrolled in this study. The age of
the patients ranged from 9 to 16 years (median, 11 years).
Diagnosis of JIA followed the criteria established in the
International League of Associations for Rheumatology
(ILAR) [14]. Patients were divided into three major sub-
groups: oligoarticular JIA, polyarticular JIA (including
five extended oligoarticular JIA) and systemic JIA. All
patients had active disease. Active disease was defined
by the presence of joint swelling or limitation of move-
ment with either pain on movement or tenderness [15].
In systemic JIA, fever and laboratory evaluation of
erythrocyte sedimentation rate (ESR) and C‐reactive pro-
tein (CRP) levels were used as additional parameters for
disease activity. All patients were subjected to proper
history taking placing special focus on number of af-
fected joints, and medications used to treat JIA at the
time of enrollment; thorough clinical examination and
radiographs were performed to the hands and feet to de-
tect any erosions or joint space narrowing.
One hundred healthy children and adolescents, of
comparable age and gender; who attended Pediatric
Department for preoperative evaluation for elective sur-
gery, were enrolled as control group. Patients and controls
belonged to the same ethnic group: African Caucasian.
Blood sampling
Blood samples were drawn from all subjects at admis-
sion and divided into two portions: 2 ml of whole blood
was collected into tubes containing EDTA, for genomic
DNA extraction. Serum were separated immediately
from remaining part of the sample and stored at −20 °C
till the time of analysis.
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Genomic DNA extraction
Genomic DNA from venous blood samples of JIA patients
and healthy controls were extracted using a genomic DNA
extraction kit (Puregene Blood Kit, Gentra, Valencia, USA)
according to the manufacturer’s protocol. DNA quantifica-
tion was done using an Eppendorf Bio Photometer
(New York, USA). DNA was stored at −20 °C.
IL10 genotyping
All subjects were genotyped for IL10- polymorphism by
amplification refractory mutation system (ARMS)-PCR
methodology. For the polymorphism at position – 1082
of interleukin-10, a 238 base-pair region was amplified by
using the sense primers 5'TTCCCCAGGTAGAGCAAC
ACT-3' and the antisense primer 5'GATGGGGTGGA
AGAAGTTGAA-3'. For the polymorphisms at positions
−819 and −592 of interleukin-10, a 467 base-pair region
was amplified using the sense primer 5'AACTTCTTCC
ACCCCATCTTT-3' and antisense primer 5'-ATCCTC
AAAGTTCCCAAGCAG-3'. as described before [16]. A
25-μl PCR reaction mixture contained 10 ng of genomic
DNA, 10 pmol of each of 5' -or 3' - primer, 100 μmol/L
dNTP, 50 mmol/L KCL, 10 mmol/L Tris-HCl (pH 8.3)
1.5 mmol/L Mgcl2 and 1 U of AmpliTaq polymerase. Am-
plifications were performed using a Perkin-Elmer 2400
thermal cycler according the following parameters: 95 °C
for 3 min followed by 29 cycles of 95 °C for 30 s, 64 °C for
20 s, and 72 °C for 30 s. A final extension at 72 °C was
performed for 10 min. PCR products were digested over-
night at 37 °C using 2.5 U of restriction enzyme. The
digested products were analyzed on a 2% agarose gel
stained with ethidium bromide.
Measurement of serum interleukin-10 (IL-10) levels
IL-10 plasma levels were measured using an enzyme-
linked immunosorbent assay (ELISA; CLB, Pelikine
Compact human IL-10 ELISA kit, Amsterdam, The
Netherlands). The sensitivity of the assay was 1 pg/ml
and the assay was performed according to the manufac-
turer’s instructions. The manufacturer reports an intra-
assay coefficient of variation of less than 10% and an
inter-assay coefficient of variation of less than 10%.
Statistical analysis
IL-10 genotype and allele frequencies in patients and
controls were tested for Hardy-Weinberg equilibrium.
Chi-square test was used to determine differences in the
frequencies of the different IL-10 genotypes between pa-
tients and controls and between clinical subtypes within
JIA patients. The odds ratio (OR) and 95% confidence
interval (95% CI) were calculated for disease susceptibility
and clinical subtypes in relation to the studied IL-10
(SNP) gene polymorphisms. The Student t test and ana-
lysis of variance were used to compare numeric variables
within groups, depending on the distribution of the data.
P value < 0.05 was considered to be statistically significant.
All data were analyzed using the Epi Info statistical soft-
ware (version 6.2, World Health Organization, Geneva,
Switzerland).
Results
Our study included 100 patients with JIA, their age
ranged from 9 to 16 years (median 11 years), 35 males
and 65 females and 100 healthy control subjects whose
clinical characteristics are listed in Table 1. The control
group were age and gender matched to patients with
JIA. The mean age at onset of JIA in the patients was
9.7 years and mean disease duration was 3.5 years.
Of these patients, 23 (23%) had systemic JIA, 31(31%)
had polyarticular JIA (nine patients were RF positive),
and 46(46%) had oligoarticular JIA. On admission, 16%
of JIA patients were receiving a non-steroidal anti-
inflammatory agent (NSAIDS), 29% were on NSAIDS
and methotrexate(MTX), 28% were on NSAIDS and
steroids,24% were on triple therapy of NSAIDS, MTX,
steroids, and 3% were on NSAIDS, MTX, biologic agents
(Table 1).
Distribution of IL-10 genotypes, alleles and serum
IL-10 levels in patients with JIA and controls are
summarized in Table 2. Both groups were in Hardy-
Weinberg equilibrium, with no significant chi-squared
values for the observed and expected genotype
frequencies.
The IL-10-1082 genotype distribution differed between
patients with JIA and healthy controls. The AA
Table 1 Baseline clinical and laboratory data of patients with






Age, years 7.5 (5–16) 7.7 (5–16) >0.05a
Gender (M/F) 35/65 39/61 >0.05b
Subtype of JIA :
Systemic 23 (23%) - -
Polyarticular 31 (31%) - -
Oligoarticular 46 (46%)
Age at onset of JIA (years) 6.7 ± 1.4 - -
Medications used on admission
NSAIDS % alone 16 (16%) - -
NSAIDS, MTX 29 (29%) - -
NSAIDS, steroids 28 (28%)
NSAIDS, MTX, steroids 24 (24%)
NSAIDS, MTX, biologic 3 (3%)
Abbreviations: IL10 interleukin 10
Data are presented as median (Range) or mean ± SD
P value < 0.05 indicates a significant difference
aMann-Whitney U test. bChi-square test
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homozygous genotype was overrepresented (23%) among
JIA patients, compared with controls (10%). Homozy-
gous subjects had a 2.7 fold increased risk of develop-
ing JIA (OR = 2.7; 95% CI: 1.1–6.4; P <0.05), while
genotypes AG/GG were not representative for JIA pa-
tients (OR = 0.37; 95% CI: 0.15–0.88; P <0.05);
Table 2.
Of note, we found a significant increase in the fre-
quency of the A allele (57.5%, OR: 1.5; 95% CI: 1.03–2.3;
P <0.05) at the −1082 position in IL-10 gene among JIA
patients; where a concomitant significant decrease in the
frequency of the G allele at the same position was ob-
served compared to the control group (42.5%, OR: 0.6;
95% CI: 0.4–0.9; P <0.05); Table 2.
On the other hand, no significant differences were
found between the 2 groups in the genotype or allele
frequencies for the −819 and −592 positions, which
shows linkage disequilibrium; (P >0.05), Table 2. Complete
linkage disequilibrium was observed between the −819
and −592 alleles. All the samples homozygous for allele C
at −819 were homozygous for allele C at −592, and all the
samples homozygous for allele T at −819 were homozy-
gous for A at −592; furthermore, heterozygote samples at
position −819 were invariably heterozygous at −592.
Therefore, −819 and −592 genotypes and alleles occurred
at identical frequencies (Table 2).
We therefore examined the IL-10 genotypes of the JIA
patients with regard to clinical and laboratory parame-
ters. No significant differences were observed when we
analyzed IL-10 genotypes according to gender, presence
of rheumatoid factor, extra-articular manifestations or
mean disease duration.
Our data revealed that patients with JIA had serum
IL-10 levels similar to the control group (7.4 ± 1.5 pg/ml
vs 5.6 ± 1.3 pg/ml; P >0.05); Table 2.
Interestingly, when our patients were evaluated for
their clinical subtypes of JIA, there was a significant
positive association between the IL-10 (-1082) AA geno-
type and susceptibility to polyarticular JIA (OR: 4.3; 95%
CI: 1.5–12.7 for the AA genotype; P <0.01); Table 3. On
the other hand, no significant association was evident
between genotype or allele frequencies for the −819
and −592 positions and different clinical subtypes of
JIA among studied patients; Table 3.
We observed that patients with polyarticular JIA
did show significantly lower serum IL-10 levels (2.5 ±
1.3 pg/ml) compared to those with systemic JIA (5.7 ± 1.5
pg/ml) and patients with oligoarticular JIA (9.6 ± 1.7 pg/ml);
P <0.01, Table 3.
Of note, we observed that patients with the IL-10
(-1082) AA genotype had significantly lower serum IL-10
levels (2.3 ± 0.9 pg/ml) compared to those with AG geno-
type (7.6 ± 1.5 pg/ml) and GG genotype (9.5 ± 1.2 pg/ml);
P < 0.01, respectively. The mean serum IL-10 level was
3.5 ± 0.8 pg/ml for the A allele vs 10.7 ± 1.4 pg/ml for
the G allele; P < 0.01, Table 4. However, we could not
find any significant association between IL-10 geno-
type or allele frequencies and serum IL-10 levels for
the −819 and −592 positions in studied patients with
JIA (P > 0.05); Table 4.
Table 2 Distribution of IL-10 genotypes, alleles and serum IL-10 levels in patients with Juvenile idiopathic arthritis (JIA) and
control group
Genotype Patient group Control group OR (95% CI) P
n (100) % n (100) %
IL-10 (-1082) AA 23 (23) 10 (10) 2.7 (1.1–6.4) <0.05
AG 69 (69) 73 (73)
GG 8 (8) 17 (17)
Alleles
A 115 (57.5) 93 (46.5) 1.5 (1.03–2.3) < 0.05
G 85 (42.5) 107 (53.5) 0.6 (0.4–0.9)
−819/-592 TT/AA 23 (23) 19 (19) > 0.05
CT/CA 65 (65) 71 (71)
CC/CC 12 (12) 10 (10)
Alleles
T/A 111 (55.5) 109 (54.5) > 0.05
C/C 89 (44.5) 91 (45.5)
Serum IL10 (pg/ml) 7.4 ± 1.5 5.6 ± 1.3 > 0.05a
Abbreviations: IL-10 interleukin-10, OR odds ratio, CI 95% confidence interval
Values in parentheses are percentages or data are presented as mean ± SD
P value < 0.05 indicates a significant difference. Chi-square test. aStudent t-test
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Discussion
Juvenile Idiopathic Arthritis (JIA) is the most common
chronic arthritis in children worldwide. Children with
JIA can experience delayed and restricted growth, with
an estimated 49% of affected children end up with severe
functional limitations [17].
A complex interaction between individual gene suscepti-
bility, cytokines activation, and various environmental
triggers may lead to an immune imbalance that subse-
quently results in articular and systemic manifestations of
JIA [10]. Cytokines play a pivotal role in immune response
and inflammation. Among these cytokines, IL-10 is a po-
tent pleiotropic cytokine that is produced primarily by
monocytes and to a lesser extent by Th-2 lymphocytes.
This cytokine has the capacity to inhibit the synthesis of
pro-inflammatory cytokines such as IL-6, IL-2, IFN-γ, and
TNF-α [18]. An association between the polymorphisms
of IL-10 gene and various inflammatory and autoimmune
diseases including Juvenile Rheumatoid Arthritis [19],
Behcet’s disease, non-infectious uveitis, and Type 1 dia-
betes have been reported [20, 21].
Because of potential immune-modulatory effects of IL-
10 and its importance as a major anti-inflammatory
cytokine, IL-10 gene polymorphisms might affect indi-
vidual susceptibility to JIA.
In the present study, we found that IL-10- AA gene
variant and A allele at the –1082 position were overrep-
resented in patients with JIA compared to the control
group. In addition, we observed that individuals with the
AA genotype had a 2.7-fold higher risk for developing
JIA, thus revealing that patients were more susceptible
to JIA. Furthermore, we detected a significant negative
association between JIA and the G allele at the −1082
position (OR: 0.6; P <0.05) indicating that this associ-
ation could represent a protective effect against JIA.
However, we did not find any significant association
between the genotype or allele frequencies and suscepti-
bility to JIA for the −819 and −592 positions of the IL-
10 promoter regions.
Several recent studies revealed that polymorphisms of
various cytokine genes may alter gene expression, and
lead to the development of JIA or change its clinical
Table 4 Association of IL-10 genotypes and alleles with serum
IL-10 levels in patients with JIA
Gene polymorphism Genotype/Alleles Serum IL10 (pg/ml) P
IL-10 (−1082) AA 2.3 ± 0.9 <0.01a
AG 7.6 ± 1.5
GG 9.5 ± 1.2
Alleles
A 3.5 ± 0.8 <0.01b
G 10.7 ± 1.4
IL-10 −819/−592 TT/AA 8.4 ± 1.5 >0.05a
CT/CA 7.8 ± 1.7
CC/CC 9.7 ± 1.3
Alleles T/A 7.2 ± 1.3 >0.05b
C/C 9.5 ± 1.6
Abbreviations: IL10 interleukin-10
Data are presented as mean ± SD
P value < 0.05 indicates a significant difference
aCalculated by ANOVA test bStudent t-test
Table 3 Comparison of Genotype and Allele Frequency of IL-10 Polymorphisms between different clinical subtypes of JIA among
studied patients
Genotype sJIA polyJIA oligoJIA OR (95% CI) P
n = 23 (%) n = 31 (%) n = 46 (%)
IL-10 (-1082) AA 6 (26) 13 (42) * 4 (9) 4.3 (1.5–12.7) < 0.01
AG 16 (70) 15 (48) 38 (82)
GG 1 (4) 3 (10) 4 (9)
Alleles
A 28 (61) 41 (66) 46 (50) > 0.05
G 18 (39) 21 (34) 46 (50)
−819/−592 TT/AA 5 (22) 8 (26) 10 (22) > 0.05
CT/CA 14 (61) 17 (55) 34 (74)
CC/CC 4 (17) 6 (19) 2 (4)
Alleles
T/A 24 (55) 33 (54) 54 (17) > 0.05
C/C 22 (44) 29 (45) 38 (17)
Serum IL10 (pg/ml) 5.7 ± 1.5 2.5 ± 1.3 9.6 ± 1.7 < 0.01a
Abbreviations: IL-10, interleukin-10, sJIA systemic Juvenile idiopathic arthritis, poly JIA polyarticular Juvenile idiopathic arthritis, oligoJIA oligoarticular Juvenile
idiopathic arthritis, OR odds ratio, CI 95% confidence interval
Values in parentheses are percentages or data are presented as mean ± SD
*P value < 0.05 indicates a significant difference. Chi-square test. aANOVA-test
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manifestations [22–27]. An earlier study by Huizinga et
al. [26] reported a lower IL-10 mRNA content in syn-
ovial biopsies from adult patients with destructive joint
disease compared to those with an inflammatory but
non-destructive joint disease. This research revealed that
IL-10 promoter genotype could predict joint destruction.
The authors added that the presence of the allele associ-
ated with less joint destruction was correlated with
higher IL-10 production, suggesting a protective role
of IL-10 in RA. Crawley et al. [27] demonstrated that
patients with juvenile RA with more than four joints
affected were more likely to have a particular IL‐10
genotype different from those with fewer than four
joints affected.
Our study confirm and extend these findings as a
significant positive association was evident between the
IL-10 (-1082) AA genotype and susceptibility to polyarti-
cular JIA among studied patients (OR: 4.3; P <0.01). In
addition, we observed that JIA patients with the AA
genotype had significantly lower serum IL-10 levels
compared to those with the AG and GG genotypes.
Furthermore, we found that the A allele at the same
position was associated with lower serum IL-10 levels,
meanwhile the G allele was correlated with higher IL-10
levels among studied JIA patients. These results were
concordant with those of Stanilova et al. [28] who
reported that the A to G switch at position −1082of the
IL-10 gene was associated with increased IL-10 produc-
tion, and the AA, AG, and GG genotypes being associ-
ated with low, intermediate, and high interleukin −10
production, respectively.
In accordance with our results, Crawley et al. [27] studied
IL10 gene SNPs (at −1082A/G, −819C/T, and −592A/C) on
genomic DNAs of 444 Caucasian children with JIA, com-
pared to 274 healthy control children. The authors found
an increased frequency of the ATA haplotype in patients
with extended OJIA. They also reported that there is a
transcriptional variation in IL-10 production among
different genotypes. Their findings confirm an associ-
ation between the “low” IL-10–producing haplotype
and disease severity in children with oligoarticular-
onset JIA that extends to polyarthritis.
In the current study, no significant association was
evident between Il-10 gene variants and susceptibility to
systemic onset JIA. By contrast, a study performed by
Fife et al. [29] from the UK identified increased prevalence
of the IL10-1082 A allele, associated with low IL10 pro-
duction, in patients with systemic onset JIA. Omoyinmi et
al. [30] confirmed that two IL-10 genetic variants
(rs1878672 and rs1800896) showing some evidence of
association with systemic onset JIA in Caucasian popula-
tion. It may be assumed that interaction between IL10 and
other cytokines in antigen presentation and T cell
polarization pathways could determine the phenotype of
the disease. Certainly, the small number of studies con-
cerning cytokine gene polymorphisms, particularly in
Caucasian population, makes it difficult to express expli-
citly the hypotheses or concepts.
Experimental models of collagen-induced arthritis
revealed that recombinant IL-10 decreases the inci-
dence, delays the onset, and reduces the severity of
arthritis [31]. An earlier study by Joosten et al. [32]
confirmed that the addition of exogenous IL‐10 in
these models also had a clear chondroprotective effect.
Moreover, synovial tissue cultures indicated that IL‐10
functions by inhibition of the production of IL‐1,
TNF-α, and matrix metalloproteinases and induces the
production of tissue inhibitor of metalloproteinases 1
(TIMP 1). These metalloproteinases are responsible
for cartilage degradation. Therefore, a lack of IL-10
can lead to increased expression of metalloproteinases
and reduced TIMP 1 expression, allowing joint de-
struction [33].
Of note, we observed that patients with polyarticular
JIA did show significantly lower serum IL-10 levels com-
pared to patients with systemic JIA and those with
oligoarticular subtypes. Our results were different from
those of Prahalad et al. [10] who reported that IL10 was
significantly elevated in polyarticular as well as systemic
subtypes of JIA. However, we could not find any signifi-
cant difference between JIA cases and controls as
regards serum IL-10 levels as they did. The systemic
concentrations of IL10 are mainly regulated at the level
of expression, because IL10 is rapidly cleared from the
plasma as it has a plasma half-life of only a few hours
[18]. Therefore, this discrepancy may be attributable to
methodological issues, such as test specimen (serum ver-
sus plasma) and assay methodology or to the differences
in the size of the cohorts. However, more studies on
cytokine profiles in patients with JIA are needed for a
definite conclusion.
On the other hand, no significant association was evi-
dent between different clinical subtypes of JIA or serum
IL-10 levels and the genotype or allele frequencies for
the −819 and −592 positions of the IL-10 promoter
regions.
A few studies in the literature concerned the associ-
ation of human IL-10 gene polymorphisms with JIA
and the susceptibility to JIA [27, 29, 30, 34]. To our
knowledge, ours is the first such study performed in an
Egyptian population. However, the small sample size
was one of our limitations in this study; we suggest that
multicenter approaches may be necessary to attain
larger sample size. Cytokine profile was not measured
during remission as all studied JIA patients had an
active disease. Therefore, the patterns of cytokine
expression could not be determined. Another limita-
tion in our study was that IL‐10 production may be
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altered in many children with arthritis because of the
treatment they receive, which includes both glucocor-
ticoids and MTX; these are both known to affect IL‐
10 production.
Conclusion
We demonstrate for the first time, to the best of our
knowledge, that the presence of an A allele or AA gene
variant at the −1082 position of the promoter region of
the interleukin-10 gene may constitute risk factors for
developing JIA in Egyptian children and adolescents.
Moreover, we observed a significant positive association
between the IL10 –1082 AA gene variant and suscepti-
bility to polyarticular JIA.
Further studies and more genetic information on eth-
nicities from different parts of the world will provide an
additional understanding of the possible role of cytokine
gene polymorphisms in JIA aiming to improve diagnosis,
assess severity, and thus seek for new therapeutic mo-
dalities of such disease.
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